Cibus (CBUS) Stock Price, News & Analysis

Company Overview

Cibus, Inc. is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships. Cibus collaborates with seed companies, growers and research institutions to advance commercial trait pipelines for crops such as canola, pennycress and potato. By applying its RTDS technology, Cibus aims to shorten development timelines and reduce regulatory complexity compared with traditional genetic modification approaches.

Headquartered in San Diego, California, Cibus serves customers and partners across North America and Europe. The company maintains research and development facilities dedicated to molecular biology, genomics and field-based trait evaluation. Through strategic alliances, Cibus has expanded its global footprint, offering tailored solutions to support sustainable agriculture and meet evolving market needs.

Cibus is led by an experienced management team with deep expertise in agricultural biotechnology, genomics and crop sciences. The leadership group guides the company’s efforts to bring innovative, non-transgenic trait solutions to market, positioning Cibus at the forefront of the next generation of precision breeding technologies.

Key Stats

• Today's Range: $1.32 to $1.39
• 50-Day Range: $1.25 to $1.75
• 52-Week Range: $1.20 to $6.10
• Volume: 105,999 shs
• Average Volume: 262,871 shs
• Market Capitalization: $74.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Cibus Stock Analysis - MarketRank™

Cibus scored higher than 51% of companies evaluated by MarketBeat, and ranked 104th out of 155 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cibus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Cibus has a consensus price target of $22.00, representing about 1,523.6% upside from its current price of $1.36.

Amount of Analyst Coverage

Cibus has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cibus are expected to decrease in the coming year, from ($2.96) to ($3.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cibus is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cibus is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cibus has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.91% of the float of Cibus has been sold short.

Short Interest Ratio / Days to Cover

Cibus has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cibus has recently increased by 0.81%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cibus does not currently pay a dividend.

Dividend Growth

Cibus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.91% of the float of Cibus has been sold short.

Short Interest Ratio / Days to Cover

Cibus has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cibus has recently increased by 0.81%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Cibus has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Consumer Staples companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cibus this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 2 people have added Cibus to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cibus insiders have not sold or bought any company stock.

Percentage Held by Insiders

49.40% of the stock of Cibus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.81% of the stock of Cibus is held by institutions.

CBUS Stock Analysis - Frequently Asked Questions

How have CBUS shares performed this year?

Cibus' stock was trading at $2.78 at the start of the year. Since then, CBUS shares have decreased by 51.3% and is now trading at $1.3550.

How were Cibus' earnings last quarter?

Cibus, Inc. (NASDAQ:CBUS) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.08. The company earned $0.93 million during the quarter, compared to the consensus estimate of $1.15 million. Cibus had a negative net margin of 5,681.55% and a negative trailing twelve-month return on equity of 83.67%.
Read the conference call transcript.

When did Cibus IPO?

Cibus (CBUS) raised $100 million in an initial public offering on Thursday, February 14th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO.

Who are Cibus' major shareholders?

Cibus' top institutional shareholders include Gratia Capital LLC (2.62%), Geode Capital Management LLC (0.79%), Jane Street Group LLC (0.46%) and Raymond James Financial Inc. (0.16%). Insiders that own company stock include Gregory Francis William Gocal, Carlo Broos and Gerhard Prante.
View institutional ownership trends.

How do I buy shares of Cibus?

Shares of CBUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cibus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cibus investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V), Netflix (nflx) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: AGRI OPERATIONS
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:CBUS
• Previous Symbol: NASDAQ:CBUS
• CIK: 1705843
• Web: www.cibus.com
• Phone: (858) 450-0008
• Fax: N/A
• Employees: 48
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cibus: $22.00
• High Price Target: $25.00
• Low Price Target: $17.50
• Potential Upside/Downside: +1,511.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$251.39 million
• Net Margins: -5,681.55%
• Pretax Margin: -6,255.98%
• Return on Equity: -83.67%
• Return on Assets: -20.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.78
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $4.26 million
• Price / Sales: 17.38
• Cash Flow: $3.90 per share
• Price / Cash Flow: 0.35
• Book Value: $3.11 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 54,240,000
• Free Float: 27,444,000
• Market Cap: $74.04 million
• Optionable: Optionable
• Beta: 1.68